Combining the smac mimetic lcl161 with gemcitabine plus cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

HIGHLIGHTS

• who: Sunisa Prasopporn and collaborators from the Qilu Hospital of Shandong University United States have published the article: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma, in the Journal: (JOURNAL)
• what: The authors aimed to identify the newly emerging therapeutic targets in GEM/CIS-resistant CCA cells by leveraging the acquired vulnerability of the CCA cells that grew under GEM/CIS treatment in the hope that inhibition of the acquired target would synergize with GEM/CIS and simultaneously block the escape of CCA . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.